Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma

BACKGROUND: Immunotherapy, including checkpoint inhibition, has remarkably improved prognosis in advanced melanoma. Despite this success, acquired resistance is still a major challenge. The T cell costimulatory receptor TNFRSF9 (also known as 4-1BB and CD137) is a promising new target for immunother...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:EBioMedicine
Autors principals: Fröhlich, Anne, Loick, Sophia, Bawden, Emma Grace, Fietz, Simon, Dietrich, Jörn, Diekmann, Eric, Saavedra, Gonzalo, Fröhlich, Holger, Niebel, Dennis, Sirokay, Judith, Zarbl, Romina, Gielen, Gerrit H., Kristiansen, Glen, Bootz, Friedrich, Landsberg, Jennifer, Dietrich, Dimo
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2020
Matèries:
Research paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6997575/
https://ncbi.nlm.nih.gov/pubmed/32028068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.102647
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars